China Medtech Joint Ventures – Ordeal Or Adventure? Part 1
This article was originally published in PharmAsia News
Executive Summary
Setting up a joint venture with a Chinese partner offers one access route. In the first of a two-part feature looking at companies’ experiences breaking into China, Clinica’s Tina Tan speaks to Raymond Akers, executive chairman of Akers Biosciences, to learn about his journey to signing a deal with a Chinese JV partner and the challenges he faced.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.